Biosplice Therapeutics, Inc.
Clinical trials sponsored by Biosplice Therapeutics, Inc., explained in plain language.
-
New knee injection shows promise for osteoarthritis pain
Disease control CompletedThis study tested a new drug called lorecivivint (SM04690) injected into the knee for people with moderate to severe knee osteoarthritis. 101 participants received two injections six months apart and were followed for a year. The goal was to see if the drug is safe and improves b…
Phase 2 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
One shot for knee pain? trial tests a new injection for osteoarthritis
Symptom relief CompletedThis trial tests whether a single injection of lorecivivint into the knee can reduce pain and improve function in people with moderate to severe knee osteoarthritis. About 499 adults aged 40 to 80 will receive either the drug or a placebo injection, and researchers will compare c…
Phase 3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
One-Shot knee treatment could ease arthritis pain for over a year
Symptom relief CompletedThis study tested a single injection of lorecivivint into the knee joint of 501 people with moderate-to-severe knee osteoarthritis. The goal was to see if it reduces pain and improves function over 56 weeks compared to a placebo. Participants reported their pain levels weekly, an…
Phase 3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
One shot to ease knee pain? new drug shows promise in large trial
Symptom relief CompletedThis study tested a single injection of a drug called lorecivivint in the knee joint of 496 people with moderate to severe knee osteoarthritis. The goal was to see if it reduces pain and improves function compared to a placebo (fake injection) over 28 weeks. Participants reported…
Phase 3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC